{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T14:55:28Z","timestamp":1781708128712,"version":"3.54.5"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T00:00:00Z","timestamp":1687219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T00:00:00Z","timestamp":1687219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004434","name":"Universit\u00e0 degli Studi di Firenze","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004434","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Aim<\/jats:title>\n                <jats:p>The risk for Herpes zoster (HZ) and its complications is higher in people with diabetes mellitus (DM). Our aim is to assess efficacy and effectiveness of the currently available live-attenuated zoster vaccine (LZV) and recombinant zoster vaccine (RZV) in adults with DM.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A Systematic Review and Meta-analysis of clinical trials and observational studies comparing incidence of HZ and its complications in vaccinated and unvaccinated people with DM was performed, on PubMed, Cochrane, Clinical Trials.gov and Embase databases, up to January 15th, 2023. Risk of bias was assessed through the Cochrane Collaboration tool and the Newcastle\u2013Ottawa Scale. The protocol was registered on the PROSPERO website (CRD42022370705).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Only three observational studies reported LZV efficacy and effectiveness in people with DM. A lower risk for HZ infection (MH-OH Ratio 95% CI\u2009=\u20090.52 [0.49, 0.56] was observed, for unadjusted analysis, and 0.51 [0.46, 0.56] for adjusted analysis, both with <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.00001 and no heterogeneity). No data on LZV safety were reported. A pooled analysis of two trials comparing RZV and placebo, showed a reduced risk for HZ incidence: (95% CI Odds Ratio: 0.09 [0.04\u20130.19]), with no difference in severe adverse events and mortality.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In our meta-analysis of three observational studies LZV showed a 48% effectiveness in reducing HZ incidence in adults with diabetes whereas in a pooled analysis of two RCTs, RZV showed a 91% efficacy. No data are available on the effects of vaccination on the incidence and severity of HZ-related complications among subjects with diabetes.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00592-023-02127-7","type":"journal-article","created":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T18:01:51Z","timestamp":1687284111000},"page":"1343-1349","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Efficacy and effectiveness of Herpes zoster vaccination in adults with diabetes mellitus: a systematic review and meta-analysis of clinical trials and observational studies"],"prefix":"10.1007","volume":"60","author":[{"given":"Giovanni Antonio","family":"Silverii","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Clerico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Fornengo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Gabutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Sordi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ottavia","family":"Peruzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Tafuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Mannucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8163-7710","authenticated-orcid":false,"given":"Ilaria","family":"Dicembrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,20]]},"reference":[{"issue":"3","key":"2127_CR1","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1056\/NEJMcp1302674","volume":"369","author":"JI Cohen","year":"2013","unstructured":"Cohen JI (2013) Herpes Zoster. N Engl J Med 369(3):255\u2013263. https:\/\/doi.org\/10.1056\/NEJMcp1302674","journal-title":"N Engl J Med"},{"issue":"11","key":"2127_CR2","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1001\/archinte.1997.00440320105010","volume":"157","author":"K Galil","year":"1997","unstructured":"Galil K, Choo PW, Donahue JG, Platt R (1997) The sequelae of herpes zoster. Arch Intern Med 157(11):1209\u20131213","journal-title":"Arch Intern Med"},{"issue":"5","key":"2127_CR3","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/NRL.0b013e31811e9d6d","volume":"13","author":"S Kawajiri","year":"2007","unstructured":"Kawajiri S, Tani M, Noda K, Fujishima K, Hattori N, Okuma EY (2007) (2007) Segmental Zoster Paresis of limbs: report of three cases and review of literature. Neurol 13(5):313\u2013317. https:\/\/doi.org\/10.1097\/NRL.0b013e31811e9d6d","journal-title":"Neurol"},{"issue":"3","key":"2127_CR4","first-page":"92","volume":"42","author":"M Votrubec","year":"2013","unstructured":"Votrubec M, Thong EI (2013) Neuropathic pain\u2013a management update. Aust Fam Phys 42(3):92\u201397","journal-title":"Aust Fam Phys"},{"issue":"2","key":"2127_CR5","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jinf.2014.08.018","volume":"70","author":"K Hillebrand","year":"2015","unstructured":"Hillebrand K, Bricout H, Schulze-Rath R, Schink T, Garbe E (2015) Incidence of herpes zoster and its complications in Germany, 2005\u20132009. J Inf 70(2):178\u2013186. https:\/\/doi.org\/10.1016\/j.jinf.2014.08.018","journal-title":"J Inf"},{"issue":"10","key":"2127_CR6","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1212\/WNL.0b013e3182a3516e","volume":"81","author":"BP Yawn","year":"2013","unstructured":"Yawn BP, Gilden D (2013) The global epidemiology of herpes zoster. Neurology 81(10):928\u2013930. https:\/\/doi.org\/10.1212\/WNL.0b013e3182a3516e","journal-title":"Neurology"},{"issue":"6","key":"2127_CR7","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1086\/528696","volume":"197","author":"MJ Levin","year":"2008","unstructured":"Levin MJ et al (2008) Varicella-Zoster virus-specific immune responses in elderly recipients of a Herpes Zoster vaccine. J Infect Dis 197(6):825\u2013835. https:\/\/doi.org\/10.1086\/528696","journal-title":"J Infect Dis"},{"issue":"10","key":"2127_CR8","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1086\/644646","volume":"200","author":"S Okamoto","year":"2009","unstructured":"Okamoto S, Hata A, Sadaoka K, Yamanishi K, Mori Y (2009) Comparison of Varicella-Zoster Virus-specific immunity of patients with diabetes mellitus and healthy individuals. J Infect Dis 200(10):1606\u20131610. https:\/\/doi.org\/10.1086\/644646","journal-title":"J Infect Dis"},{"key":"2127_CR9","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/S1386-6532(10)70002-0","volume":"48","author":"AA Gershon","year":"2010","unstructured":"Gershon AA, Gershon MD, Breuer J, Levin MJ, Oaklander AL, Griffiths PD (2010) Advances in the understanding of the pathogenesis and epidemiology of herpes zoster\u00bb. J Clin Virol 48:S2\u2013S7. https:\/\/doi.org\/10.1016\/S1386-6532(10)70002-0","journal-title":"J Clin Virol"},{"issue":"1","key":"2127_CR10","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1186\/s12879-022-07479-z","volume":"22","author":"SL Cadogan","year":"2022","unstructured":"Cadogan SL, Mindell JS, Breuer J, Hayward A, Warren-Gash C (2022) Prevalence of and factors associated with herpes zoster in England: a cross-sectional analysis of the Health Survey for England. BMC Infect Dis 22(1):513. https:\/\/doi.org\/10.1186\/s12879-022-07479-z","journal-title":"BMC Infect Dis"},{"issue":"6","key":"2127_CR11","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1111\/bjd.19687","volume":"184","author":"HJ Forbes","year":"2021","unstructured":"Forbes HJ et al (2021) Incidence of acute complications of herpes zoster among immunocompetent adults in England: a matched cohort study using routine health data*. Br J Dermatol 184(6):1077\u20131084. https:\/\/doi.org\/10.1111\/bjd.19687","journal-title":"Br J Dermatol"},{"key":"2127_CR12","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.puhe.2018.10.015","volume":"167","author":"M Mareque","year":"2019","unstructured":"Mareque M, Oyag\u00fcez I, Morano R, Casado MA (2019) Systematic review of the evidence on the epidemiology of herpes zoster: incidence in the general population and specific subpopulations in Spain. Public Health 167:136\u2013146. https:\/\/doi.org\/10.1016\/j.puhe.2018.10.015","journal-title":"Public Health"},{"issue":"16","key":"2127_CR13","doi-asserted-by":"publisher","first-page":"e25292","DOI":"10.1097\/MD.0000000000025292","volume":"100","author":"S-W Lai","year":"2021","unstructured":"Lai S-W, Liu C-S, Kuo Y-H, Lin C-L, Hwang B-F, Liao K-F (2021) The incidence of herpes zoster in patients with diabetes mellitus: a meta-analysis of cohort studies\u00bb. Medicine 100(16):e25292. https:\/\/doi.org\/10.1097\/MD.0000000000025292","journal-title":"Medicine"},{"issue":"1","key":"2127_CR14","doi-asserted-by":"publisher","first-page":"ofaa005","DOI":"10.1093\/ofid\/ofaa005","volume":"7","author":"F Marra","year":"2020","unstructured":"Marra F, Parhar K, Huang B, Vadlamudi N (2020) Risk factors for Herpes Zoster infection: a meta-analysis. Open Forum Infect Dis 7(1):ofaa005. https:\/\/doi.org\/10.1093\/ofid\/ofaa005","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"2127_CR15","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1210\/clinem\/dgab675","volume":"107","author":"C-T Huang","year":"2022","unstructured":"Huang C-T, Lee C-Y, Sung H-Y, Liu S-J, Liang P-C, Tsai M-C (2022) Association between diabetes mellitus and the risk of Herpes Zoster: a systematic review and meta-analysis. J Clin Endocrinol Metabol 107(2):586\u2013597. https:\/\/doi.org\/10.1210\/clinem\/dgab675","journal-title":"J Clin Endocrinol Metabol"},{"key":"2127_CR16","doi-asserted-by":"publisher","first-page":"107983","DOI":"10.1016\/j.diabres.2019.107983","volume":"159","author":"M Saadatian-Elahi","year":"2020","unstructured":"Saadatian-Elahi M, Bauduceau B, Del-Signore C, Vanhems P (2020) Diabetes as a risk factor for herpes zoster in adults: a synthetic literature review. Diabet Res Clin Pract 159:107983. https:\/\/doi.org\/10.1016\/j.diabres.2019.107983","journal-title":"Diabet Res Clin Pract"},{"issue":"2","key":"2127_CR17","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s13300-018-0394-4","volume":"9","author":"M Papagianni","year":"2018","unstructured":"Papagianni M, Metallidis S, Tziomalos K (2018) Herpes Zoster and diabetes mellitus: a review. Diabet Ther 9(2):545\u2013550. https:\/\/doi.org\/10.1007\/s13300-018-0394-4","journal-title":"Diabet Ther"},{"issue":"1","key":"2127_CR18","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1097\/j.pain.0000000000000307","volume":"157","author":"HJ Forbes","year":"2016","unstructured":"Forbes HJ et al (2016) A systematic review and meta-analysis of risk factors for postherpetic neuralgia. Pain 157(1):30\u201354. https:\/\/doi.org\/10.1097\/j.pain.0000000000000307","journal-title":"Pain"},{"issue":"5","key":"2127_CR19","doi-asserted-by":"publisher","first-page":"2040328","DOI":"10.1080\/21645515.2022.2040328","volume":"18","author":"J-E Poirrier","year":"2022","unstructured":"Poirrier J-E et al (2022) Burden of opioid use for pain management among adult herpes zoster patients in the US and the potential impact of vaccination. Hum Vaccin Immunother 18(5):2040328. https:\/\/doi.org\/10.1080\/21645515.2022.2040328","journal-title":"Hum Vaccin Immunother"},{"issue":"11","key":"2127_CR20","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1080\/21645515.2017.1368600","volume":"13","author":"C Mu\u00f1oz-Quiles","year":"2017","unstructured":"Mu\u00f1oz-Quiles C, L\u00f3pez-Lacort M, Ampudia-Blasco FJ, D\u00edez-Domingo J (2017) Risk and impact of herpes zoster on patients with diabetes: a population-based study, 2009\u20132014. Human Vacc Immunother 13(11):2606\u20132611. https:\/\/doi.org\/10.1080\/21645515.2017.1368600","journal-title":"Human Vacc Immunother"},{"issue":"1","key":"2127_CR21","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12879-019-3719-7","volume":"19","author":"S Ohfuji","year":"2019","unstructured":"Ohfuji S et al (2019) Safety of live attenuated varicella-zoster vaccine in patients with underlying illnesses compared with healthy adults: a prospective cohort study. BMC Infect Dis 19(1):95. https:\/\/doi.org\/10.1186\/s12879-019-3719-7","journal-title":"BMC Infect Dis"},{"issue":"22","key":"2127_CR22","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa051016","volume":"352","author":"MN Oxman","year":"2005","unstructured":"Oxman MN et al (2005) A vaccine to prevent Herpes Zoster and postherpetic neuralgia in older adults. N Engl J Med 352(22):2271\u20132284. https:\/\/doi.org\/10.1056\/NEJMoa051016","journal-title":"N Engl J Med"},{"issue":"22","key":"2127_CR23","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","volume":"372","author":"H Lal","year":"2015","unstructured":"Lal H et al (2015) Efficacy of an adjuvanted Herpes Zoster subunit vaccine in older adults. N Engl J Med 372(22):2087\u20132096. https:\/\/doi.org\/10.1056\/NEJMoa1501184","journal-title":"N Engl J Med"},{"issue":"11","key":"2127_CR24","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","volume":"375","author":"AL Cunningham","year":"2016","unstructured":"Cunningham AL et al (2016) Efficacy of the Herpes Zoster subunit vaccine in adults 70 years of age or older. N Engl J Med 375(11):1019\u20131032. https:\/\/doi.org\/10.1056\/NEJMoa1603800","journal-title":"N Engl J Med"},{"issue":"10","key":"2127_CR25","doi-asserted-by":"publisher","first-page":"ofac085","DOI":"10.1093\/ofid\/ofac485","volume":"9","author":"A Strezova","year":"2022","unstructured":"Strezova A et al (2022) Long-term protection against Herpes Zoster by the adjuvanted recombinant zoster vaccine: interim efficacy, immunogenicity, and safety results up to 10 years after initial vaccination. Open Forum Infect Dis 9(10):ofac085. https:\/\/doi.org\/10.1093\/ofid\/ofac485","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"2127_CR26","doi-asserted-by":"publisher","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","volume":"67","author":"KL Dooling","year":"2018","unstructured":"Dooling KL et al (2018) Recommendations of the Advisory committee on immunization practices for use of Herpes Zoster vaccines. MMWR Morb Mortal Wkly Rep 67(3):103\u2013108. https:\/\/doi.org\/10.15585\/mmwr.mm6703a5","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"9","key":"2127_CR27","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1080\/14760584.2021.1956906","volume":"20","author":"R Parikh","year":"2021","unstructured":"Parikh R, Widenmaier R, Lecrenier N (2021) A practitioner\u2019s guide to the recombinant zoster vaccine: review of national vaccination recommendations. Exp Rev Vacc 20(9):1065\u20131075. https:\/\/doi.org\/10.1080\/14760584.2021.1956906","journal-title":"Exp Rev Vacc"},{"key":"2127_CR28","unstructured":"\u201cCalendario per la Vita\u201d Position on the utilization of the herpes zoster vaccine (HZ). Available on: http:\/\/www.igienistionline.it\/docs\/2021\/09zoster.pdf"},{"key":"2127_CR29","unstructured":"German Standing Committee on Vaccination (STIKO) at the Robert Koch Institute (RKI) Epidimiological bulletin No. 50. 2018, Available on: https:\/\/www.rki.de\/DE\/Content\/Infekt\/EpidBull\/Archiv\/2018\/Ausgaben\/50_18.pdf?__blob =publicationFile"},{"issue":"10","key":"2127_CR30","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.3390\/vaccines10101770","volume":"10","author":"A Ceccarelli","year":"2022","unstructured":"Ceccarelli A et al (2022) Adherence to Herpes Zoster (Shingles) catch-up campaign at the romagna local health authority (Italy), a multi-center retrospective observational study. Vaccines 10(10):1770. https:\/\/doi.org\/10.3390\/vaccines10101770","journal-title":"Vaccines"},{"issue":"12","key":"2127_CR31","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1099\/jmm.0.000386","volume":"65","author":"G Gabutti","year":"2016","unstructured":"Gabutti G, Valente N, Kuhdari P, Lupi S, Stefanati A (2016) Prevention of herpes zoster and its complications: from the clinic to the real-life experience with the vaccine. J Med Microbiol 65(12):1363\u20131369. https:\/\/doi.org\/10.1099\/jmm.0.000386","journal-title":"J Med Microbiol"},{"key":"2127_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.23736\/S0026-4806.19.06412-7","volume":"111","author":"S Cocchio","year":"2020","unstructured":"Cocchio S, Gallo T, Baldo V (2020) Herpes zoster vaccination status and virtuous experiences. Minerva Med 111:1. https:\/\/doi.org\/10.23736\/S0026-4806.19.06412-7","journal-title":"Minerva Med"},{"key":"2127_CR33","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/14651858.CD008858.pub4","volume":"2019","author":"AM Gagliardi","year":"2019","unstructured":"Gagliardi AM et al (2019) Vaccines for preventing herpes zoster in older adults. Cochrane Database Syst Rev 2019:11. https:\/\/doi.org\/10.1002\/14651858.CD008858.pub4","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"2127_CR34","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1080\/14760584.2020.1760098","volume":"19","author":"T Verstraeten","year":"2020","unstructured":"Verstraeten T et al (2020) Diabetes mellitus as a vaccine-effect modifier: a review. Expert Rev Vaccines 19(5):445\u2013453. https:\/\/doi.org\/10.1080\/14760584.2020.1760098","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"2127_CR35","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","volume":"10","author":"MJ Page","year":"2021","unstructured":"Page MJ et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews\u00bb. Syst Rev 10(1):89. https:\/\/doi.org\/10.1186\/s13643-021-01626-4","journal-title":"Syst Rev"},{"key":"2127_CR36","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ (Clin Res ed) 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ (Clin Res ed)"},{"issue":"7650","key":"2127_CR37","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH et al (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336(7650):924\u2013926. https:\/\/doi.org\/10.1136\/bmj.39489.470347.AD","journal-title":"BMJ"},{"issue":"8","key":"2127_CR38","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/dme.13038","volume":"33","author":"A Hata","year":"2016","unstructured":"Hata A et al (2016) Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial. Diabet Med 33(8):1094\u20131101. https:\/\/doi.org\/10.1111\/dme.13038","journal-title":"Diabet Med"},{"issue":"12","key":"2127_CR39","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1093\/ndt\/gfv432","volume":"31","author":"SM Langan","year":"2016","unstructured":"Langan SM, Thomas SL, Smeeth L, Margolis DJ, Nitsch D (2016) Zoster vaccination is associated with a reduction of zoster in elderly patients with chronic kidney disease. Nephrol Dial Transpl 31(12):2095\u20132098. https:\/\/doi.org\/10.1093\/ndt\/gfv432","journal-title":"Nephrol Dial Transpl"},{"key":"2127_CR40","doi-asserted-by":"publisher","first-page":"100007","DOI":"10.1016\/j.jvacx.2019.100007","volume":"1","author":"K Bollaerts","year":"2019","unstructured":"Bollaerts K, Alexandridou M, Verstraeten T (2019) Risk factors for modified vaccine effectiveness of the live attenuated zoster vaccine among the elderly in England. Vacc X 1:100007. https:\/\/doi.org\/10.1016\/j.jvacx.2019.100007","journal-title":"Vacc X"},{"issue":"12","key":"2127_CR41","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1093\/infdis\/jiw047","volume":"213","author":"HF Tseng","year":"2016","unstructured":"Tseng HF et al (2016) Declining effectiveness of Herpes Zoster vaccine in adults aged \u226560 years. J Infect Dis 213(12):1872\u20131875. https:\/\/doi.org\/10.1093\/infdis\/jiw047","journal-title":"J Infect Dis"},{"issue":"12","key":"2127_CR42","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1080\/21645515.2019.1627818","volume":"15","author":"L Oostvogels","year":"2019","unstructured":"Oostvogels L et al (2019) Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials. Hum Vaccin Immunother 15(12):2865\u20132872. https:\/\/doi.org\/10.1080\/21645515.2019.1627818","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"2127_CR43","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/S2666-7568(22)00039-3","volume":"3","author":"JF Mbinta","year":"2022","unstructured":"Mbinta JF, Nguyen BP, Awuni PMA, Paynter J, Simpson CR (2022) Post-licensure zoster vaccine effectiveness against Herpes Zoster and postherpetic neuralgia in older adults: a systematic review and meta-analysis. Lancet Healthy Longevity 3(4):e263\u2013e275. https:\/\/doi.org\/10.1016\/S2666-7568(22)00039-3","journal-title":"Lancet Healthy Longevity"},{"key":"2127_CR44","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4029","author":"AC Tricco","year":"2018","unstructured":"Tricco AC et al (2018) Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis\u00bb. BMJ. https:\/\/doi.org\/10.1136\/bmj.k4029","journal-title":"BMJ"},{"issue":"22","key":"2127_CR45","doi-asserted-by":"publisher","first-page":"2896","DOI":"10.1016\/j.vaccine.2019.04.014","volume":"37","author":"A McGirr","year":"2019","unstructured":"McGirr A et al (2019) The comparative efficacy and safety of herpes zoster vaccines: a network meta-analysis. Vaccine 37(22):2896\u20132909. https:\/\/doi.org\/10.1016\/j.vaccine.2019.04.014","journal-title":"Vaccine"},{"issue":"28","key":"2127_CR46","doi-asserted-by":"publisher","first-page":"3813","DOI":"10.1016\/j.vaccine.2022.05.044","volume":"40","author":"S Tafuri","year":"2022","unstructured":"Tafuri S, Bianchi FP, Stefanizzi P (2022) The public health and the question of the \u201cbest vaccine.\u201d Vaccine 40(28):3813\u20133814. https:\/\/doi.org\/10.1016\/j.vaccine.2022.05.044","journal-title":"Vaccine"},{"issue":"11","key":"2127_CR47","doi-asserted-by":"publisher","first-page":"4265","DOI":"10.1080\/21645515.2021.1971473","volume":"17","author":"M Andreoni","year":"2021","unstructured":"Andreoni M, Sticchi L, Nozza S et al (2021) Recommendations of the Italian society for infectious and tropical diseases (SIMIT) for adult vaccinations. Hum Vaccin Immunother 17(11):4265\u20134282. https:\/\/doi.org\/10.1080\/21645515.2021.1971473","journal-title":"Hum Vaccin Immunother"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-023-02127-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00592-023-02127-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-023-02127-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T19:02:36Z","timestamp":1692644556000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00592-023-02127-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,20]]},"references-count":47,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["2127"],"URL":"https:\/\/doi.org\/10.1007\/s00592-023-02127-7","relation":{},"ISSN":["1432-5233"],"issn-type":[{"value":"1432-5233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,20]]},"assertion":[{"value":"13 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"GG declares fees from Sanofi Pasteur MSD, Pfizer, GSK Biologicals SA, Sanofi Pasteur, MSD Italy, Emergent BioSolutions, Moderna and Seqirus for taking part to advisory boards, expert meetings, for acting as speaker and\/or organizer of meetings\/congresses and as principal investigator and chief of O.U. in RCTs. All the others authors have no conflict of interest to disclose directly related to this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights participations"}}]}}